Skip to content

赫力昂

US · HLN #553 按市值排名 上市于 2022
10.13 +0.19 +1.91%
实时 - 追踪5344个代码 - 心跳于458秒前 · 2026-10-16 20:02

✦ 量化合理价值 计算方式说明

接近合理价值
9.71 合理价值 ≈ 12.03 14.35
  • 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为9.71-14.35。
  • 当前价格比按平均倍数计算的合理价值(12.03)低15.8%。

估值 各估值倍数与自身5年区间的对比

市净率 1.89 处于历史正常水平 第47百分位
5年平均 1.84 · 在Drug Manufacturers - Specialty & Generic中排名第37/70
市盈率 19.46 低于历史水平 第15百分位
5年平均 24.50 · 前瞻 16.94 · 在Drug Manufacturers - Specialty & Generic中排名第12/25
市销率 2.78 处于历史正常水平 第41百分位
5年平均 2.87 · 前瞻 2.66 · 在Drug Manufacturers - Specialty & Generic中排名第45/80

同业对比 Drug Manufacturers - Specialty & Generic

公司 市值 市盈率(TTM) 市净率 股息率
赫力昂 (HLN) 44.55B 21.06 2.05 1.88%
Takeda Pharmaceutical (TAK) 62.84B -59.43 1.31 3.04%
Teva Pharmaceutical Industries (TEVA) 48.40B 69.17 6.24 0.00%
Zoetis (ZTS) 32.80B 12.95 10.42 2.60%
United Therapeutics (UTHR) 22.87B 19.10 3.57 0.00%
Viatris (VTRS) 21.43B -50.42 1.50 2.57%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★★ 合理价值10.38 经济护城河Wide 不确定性Low

当前股价低于晨星合理价值估算2.5%。

合理价值

Haleon PLC earns a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 10% discount to our quantitative fair value estimate of $10.38 per share, which is reinforced by this estimate's low uncertainty rating.

The firm's profitability bolsters our fair value estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's earnings yield of 6.1% lies in the top 40% compared with global peers. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are cheap.

Conversely, the firm's balance sheet is potentially concerning. Excessive leverage heightens financial risk, potentially undermining a firm's value. The firm's EBITDA/interest coverage ratio of 8.5, a core component of leverage, sits in the bottom 40% globally. This gives us pause, as it can be a warning sign of financial distress if conditions don't improve. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

经济护城河

The company's excess returns on capital and superb profitability, which could persist for decades or more, warrant a wide economic moat rating. This is supported by the company's strong financial health score, which indicates a low likelihood that the company will tumble into financial distress.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:02:17 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

赫力昂 讨论区 0 条评论

发表评论